Commentary|Articles|September 11, 2025

Experts Highlight Key Topics to Watch at the 22nd International Myeloma Society Annual Meeting

Experts preview abstracts being presented at IMS, highlighting the role of MRD, bispecific antibodies, and other strategies to refine myeloma management.

The 22nd International Myeloma Society (IMS) Annual Meeting, taking place September 17–20, 2025, in Toronto, Canada, will highlight key advances across multiple myeloma research, including progress in precursor disease profiling and management, risk-adapted management strategies, immunotherapy optimization, and strategies for patients experiencing early relapse.¹ Additional sessions will spotlight late-breaking data on the predictive role of minimal residual disease (MRD), the efficacy of novel bispecific antibody combinations, and approaches for high-risk disease.

Related to this article

Iberdomide Plus Daratumumab/Dexamethasone in Multiple Myeloma | Image Credit: © LELISAT - stock.adobe.com

September 26th, 2026

Iberdomide Plus Daratumumab/Dexamethasone Improves MRD-Negative CR vs DVd in Relapsed/Refractory Myeloma

The first MRD data from the phase 3 EXCALIBER-RRMM trial support iberdomide-based triplet therapy as early as first relapse, with PFS follow-up ongoing.

D-VRd in Transplant-Eligible Newly Diagnosed Myeloma | Image Credit: © Nicat - stock.adobe.com

September 26th, 2026

Long-Term PERSEUS Data Confirm Durable PFS Benefit With D-VRd in Transplant-Eligible Newly Diagnosed Myeloma

After nearly 7 years of follow-up, daratumumab added to VRd continued to improve PFS, PFS2, and sustained MRD negativity in transplant-eligible myeloma.

$Etentamig in Triple-Class Exposed Relapsed/Refractory Myeloma | Image Credit: © Curie - stock.adobe.com$

September 25th, 2026

Etentamig Improves Response and PFS vs Standard Therapies in Triple-Class Exposed Relapsed/Refractory Myeloma

Monthly etentamig significantly improved response and PFS over standard available therapies in the phase 3 CERVINO trial, with low rates of high-grade CRS.

Cevostamab Plus Pomalidomide/Dexamethasone in BCMA-Naive Myeloma | Image Credit: © LASZLO - stock.adobe.com

September 24th, 2026

Cevostamab Plus Pomalidomide/Dexamethasone Yields Durable, Deep Responses in BCMA-Naive Relapsed/Refractory Myeloma

Extended follow-up from the phase 1b CAMMA 1 trial showed durable responses across two cevostamab dose levels, supporting selection of a recommended phase 3 regimen.

iMMagine-1 vs CARTITUDE-1 MAIC in Multiple Myeloma | Image Credit: © Tongpoon - stock.adobe.com

September 24th, 2026

iMMagine-1 vs CARTITUDE-1 MAIC Shows Comparable Efficacy, Improved Safety With Anito-Cel in Relapsed/Refractory Multiple Myeloma

A MAIC found anito-cel produced response rates similar to those of cilta-cel, with fewer high-grade toxicities, in relapsed/refractory multiple myeloma.

Linvoseltamab in High-Risk Smoldering Myeloma | Image Credit: © ArtificialHorizons - stock.adobe.com

September 23rd, 2026

Linvoseltamab Yields Deep, MRD-Negative Responses With Manageable Safety in High-Risk Smoldering Myeloma

Updated phase 2 LINKER-SMM1 data show single-agent, fixed-duration linvoseltamab produced deep, durable, and MRD-negative responses in high-risk smoldering multiple myeloma.

The top 5 OncLive TV videos of the week cover insights in breast cancer, PV, myeloma, and CLL.

September 27th, 2026

Five Under 5: Top Oncology Videos for the Week of 9/20

The top 5 OncLive TV videos of the week cover insights in breast cancer, PV, myeloma, and CLL.

September 21st, 2026

Real-World Data Reinforce Liso-Cel Efficacy in R/R MCL

Elise A. Chong, MD, discusses real-world liso-cel efficacy and safety, outpatient use, and future directions in relapsed/refractory mantle cell lymphoma.